董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dennis Fenton | 男 | Director | 65 | 21.50万美元 | 未持股 | 2017-04-24 |
| Hollings C. Renton | 男 | Chairman of our Board | 70 | 未披露 | 未持股 | 2017-04-24 |
| Hollings C. Renton | 男 | Chairman of our Board | 70 | 25.50万美元 | 未持股 | 2017-04-24 |
| Charles J. Homcy | 男 | Director | 68 | 22.30万美元 | 未持股 | 2017-04-24 |
| H. Ward Wolff | 男 | Director | 68 | 22.30万美元 | 未持股 | 2017-04-24 |
| Jeffrey W. Bird | 男 | Director | 56 | 21.85万美元 | 未持股 | 2017-04-24 |
| John H. Johnson | 男 | Director | 59 | 24.30万美元 | 未持股 | 2017-04-24 |
| Laura Brege | 女 | Director | 59 | 未披露 | 未持股 | 2017-04-24 |
| William Lis | 男 | Chief Executive Officer and Director | 52 | 690.23万美元 | 未持股 | 2017-04-24 |
| Laura Brege | 女 | Director | 59 | 21.85万美元 | 未持股 | 2017-04-24 |
| David Stump | 男 | Director | 67 | 21.35万美元 | 未持股 | 2017-04-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tao Fu | 男 | Executive Vice President, Chief Commercial and Business Officer | 45 | 269.47万美元 | 未持股 | 2017-04-24 |
| William Lis | 男 | Chief Executive Officer and Director | 52 | 690.23万美元 | 未持股 | 2017-04-24 |
| John T. Curnutte | 男 | Executive Vice President, Research and Development | 65 | 235.31万美元 | 未持股 | 2017-04-24 |
| Mardi C. Dier | 女 | Executive Vice President and Chief Financial Officer | 53 | 344.45万美元 | 未持股 | 2017-04-24 |
董事简历
中英对照 | 中文 | 英文- Dennis Fenton
-
Dennis Fenton，他担任我们的董事会成员（2015年2月以来）。从1982年到2008年，他担任Amgen公司（一个生物技术公司）的多种职务。从2000年到2008年，他曾担任执行副总裁，负责操作、制造、过程开发和质量。从1995年到2000年，他曾担任负责业务的高级副总裁。从1992年到1995年，他曾担任公司的高级副总裁，负责销售、营销和开发过程。任职Amgen公司之前，他曾担任Pfizer公司的高级研究科学家，此前曾担任Rutgers University的研究助理和研究生。他目前担任Dendreon Corporation（生物制药公司）、Hospira公司（生物制药公司）、XenoPort公司（生物制药公司）、Kythera Biopharmaceuticals公司（生物制药公司）的董事会成员。在过去的5年里，他曾任职于Genzyme Corporation的董事会。他持有Manhattan College的生物学学士学位，以及美国罗格斯大学（Rutgers University）的微生物学博士学位。
Dennis Fenton, Ph.D., has served as a member of our board of directors since March 2018. From 1981 to 2008 Dr. Fenton held numerous positions at Amgen, Inc., a biotechnology company, including Executive Vice President from 2000 until 2008 Senior Vice President of Operations from 1995 until 2000 and Senior Vice President of Sales, Marketing and Process Development from 1992 until 1995. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves on the board of directors of Sienna Biopharmaceuticals, Portola Pharmaceuticals, and Pfenex Inc. He previously served on the boards of directors of XenoPort, Inc. and Kythera Biopharmaceuticals, Inc., as well as several private company boards. Dr. Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University. - Dennis Fenton，他担任我们的董事会成员（2015年2月以来）。从1982年到2008年，他担任Amgen公司（一个生物技术公司）的多种职务。从2000年到2008年，他曾担任执行副总裁，负责操作、制造、过程开发和质量。从1995年到2000年，他曾担任负责业务的高级副总裁。从1992年到1995年，他曾担任公司的高级副总裁，负责销售、营销和开发过程。任职Amgen公司之前，他曾担任Pfizer公司的高级研究科学家，此前曾担任Rutgers University的研究助理和研究生。他目前担任Dendreon Corporation（生物制药公司）、Hospira公司（生物制药公司）、XenoPort公司（生物制药公司）、Kythera Biopharmaceuticals公司（生物制药公司）的董事会成员。在过去的5年里，他曾任职于Genzyme Corporation的董事会。他持有Manhattan College的生物学学士学位，以及美国罗格斯大学（Rutgers University）的微生物学博士学位。
- Dennis Fenton, Ph.D., has served as a member of our board of directors since March 2018. From 1981 to 2008 Dr. Fenton held numerous positions at Amgen, Inc., a biotechnology company, including Executive Vice President from 2000 until 2008 Senior Vice President of Operations from 1995 until 2000 and Senior Vice President of Sales, Marketing and Process Development from 1992 until 1995. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves on the board of directors of Sienna Biopharmaceuticals, Portola Pharmaceuticals, and Pfenex Inc. He previously served on the boards of directors of XenoPort, Inc. and Kythera Biopharmaceuticals, Inc., as well as several private company boards. Dr. Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.
- Hollings C. Renton
-
Hollings C. Renton自2017年2月起担任Zymeworks董事会成员。Renton先生于1993年3月至2008年3月担任Onyx制药公司首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx公司董事会主席。Onyx在2013年被安进公司以104亿美元的价格收购。在加入Onyx公司之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron公司的总裁兼首席运营官。1983年，Renton先生在Cetus公司担任过多种行政职务，包括1990年至1991年担任总裁，1987年至1990年担任首席运营官，1983年至1987年担任首席财务官，之后该公司于1991年被Chiron公司收购。Renton先生自2015年6月起担任AnaptysBio董事会成员。在此之前，Renton先生曾在其他四家生物制药公司任职：Portola制药公司（2010年3月至2020年7月）、Kythera生物制药公司（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。伦顿还曾于2000年3月至2016年11月担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生在密歇根大学获得工商管理硕士学位，在科罗拉多州立大学获得数学学士学位。伦顿先生是美国加利福尼亚州的居民。
Hollings C. Renton has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company,from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA. - Hollings C. Renton自2017年2月起担任Zymeworks董事会成员。Renton先生于1993年3月至2008年3月担任Onyx制药公司首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx公司董事会主席。Onyx在2013年被安进公司以104亿美元的价格收购。在加入Onyx公司之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron公司的总裁兼首席运营官。1983年，Renton先生在Cetus公司担任过多种行政职务，包括1990年至1991年担任总裁，1987年至1990年担任首席运营官，1983年至1987年担任首席财务官，之后该公司于1991年被Chiron公司收购。Renton先生自2015年6月起担任AnaptysBio董事会成员。在此之前，Renton先生曾在其他四家生物制药公司任职：Portola制药公司（2010年3月至2020年7月）、Kythera生物制药公司（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。伦顿还曾于2000年3月至2016年11月担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生在密歇根大学获得工商管理硕士学位，在科罗拉多州立大学获得数学学士学位。伦顿先生是美国加利福尼亚州的居民。
- Hollings C. Renton has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company,from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA.
- Hollings C. Renton
-
Hollings C. Renton于2000年3月加入本公司出任董事。2008年3月从Onyx制药公司（一家生物制药和生物疗法公司）退休，自1992年4月起担任董事，于1993年3月成为总裁兼首席执行官，于2003年6月成为董事会主席。从1991年到1993年，担任Chiron公司（制药公司）的总裁兼首席营运官，随后公司收购Cetus Corporation。在收购之前，自1990年至1991年担任Cetus Corporation的总裁，自1987年至1990年担任首席营运官。亦担任Affymax公司，Rigel制药和Portola制药公司的董事局成员。
Hollings C. Renton has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company,from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA. - Hollings C. Renton于2000年3月加入本公司出任董事。2008年3月从Onyx制药公司（一家生物制药和生物疗法公司）退休，自1992年4月起担任董事，于1993年3月成为总裁兼首席执行官，于2003年6月成为董事会主席。从1991年到1993年，担任Chiron公司（制药公司）的总裁兼首席营运官，随后公司收购Cetus Corporation。在收购之前，自1990年至1991年担任Cetus Corporation的总裁，自1987年至1990年担任首席营运官。亦担任Affymax公司，Rigel制药和Portola制药公司的董事局成员。
- Hollings C. Renton has served as a member of Zymeworks Bc Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company,from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA.
- Charles J. Homcy
-
Charles J. Homcy,M.D.，医学博士，从2005年7月起担任公司的董事，目前担任Portola Pharmaceuticals, Inc.的总裁兼首席执行官，该公司是一家专注于心血管疾病和炎症治疗的生物制药公司。Homcy博士，从2003年到2008年在Millennium Pharmaceuticals, Inc.——一家开发抗癌疗法的基因组学公司；从2003年到2008年在Kosan Biosciences, Inc.——一家基于天然产品开发癌症治疗的多酮类化合物的生物制药公司；从2004年到2008年在Cytokinetics,Inc 。——一家专注于心脏衰竭和癌症治疗的生物制药公司担任董事。从2003年1月至2003年11月，Homcy博士在Millennium Pharmaceuticals担任高级研发顾问，他于2002年加入了他们作为研发总裁。在此之前，从1995年到2002年，他担任COR Therapeutics, Inc.的研发执行副总裁，该公司是一家专注于心力衰竭治疗的生物制药公司；从1998年1月到2002年被Millennium Pharmaceuticals收购，他担任COR的董事。从1997年起，Homcy博士担任加州大学旧金山医学院（University of California at San Francisco Medical School）的临床医学教授和San Francisco VA Hospital的主治医生。从1994年到1995年，Homcy博士是American Cyanamid Company-Lederle Laboratories （ 现Wyeth-Ayerst Laboratories的分公司）医学研究部总裁。从1990年到1994年，Homcy博士是执行主任心血管和中枢神经系统研究部分Lederle实验室。从1991年到1995年Homcy博士还担任The Presbyterian Hospital, College of Physicians and Surgeons, at Columbia University in New York的主治医生。从1979年到1990年，他是 Massachusetts General Hospital的主治医生，以及哈佛医学院医学（Harvard Medical School）的副教授。Charles J. Homcy拥有约翰霍普金斯大学授予的医学学士学位和博士学位。
Charles J. Homcy has served as a member of our Board since September 2003 as Co-Chairman of our Board from March 2010 to May 2013 and as Chairman of our Board from September 2003 to March 2010. Since May 2010 Dr. Homcy has served as a Venture Partner of Third Rock Ventures, a venture capital firm. Since 1997 Dr. Homcy has served as Clinical Professor of Medicine, University of California at San Francisco Medical School and as an attending physician at the San Francisco Veteran’s Administration Hospital. Dr. Homcy is a co-founder of Portola and served as President and Chief Executive Officer of Portola from September 2003 to April 2010 and was employed as an adviser to Portola from May 2010 to February 2012. He served as President, Research and Development at Millennium from February 2002 to January 2003 and senior adviser of Research and Development at Millennium from January 2003 to November 2003. From May 1995 to March 2002 he served as Executive Vice President of Research and Development of COR. Dr. Homcy is currently a director on the board of MyoKardia, Inc. and Global Blood Therapeutics, Inc. as well as a member of the Board of Trustees of Johns Hopkins University. Dr. Homcy also serves as a Scientific Advisor for Cytokinetics, Inc. Dr. Homcy holds an A.B. in Biology and an M.D. from Johns Hopkins University. Dr. Homcy is also a member of the Board of Trustees of John Hopkins University. - Charles J. Homcy,M.D.，医学博士，从2005年7月起担任公司的董事，目前担任Portola Pharmaceuticals, Inc.的总裁兼首席执行官，该公司是一家专注于心血管疾病和炎症治疗的生物制药公司。Homcy博士，从2003年到2008年在Millennium Pharmaceuticals, Inc.——一家开发抗癌疗法的基因组学公司；从2003年到2008年在Kosan Biosciences, Inc.——一家基于天然产品开发癌症治疗的多酮类化合物的生物制药公司；从2004年到2008年在Cytokinetics,Inc 。——一家专注于心脏衰竭和癌症治疗的生物制药公司担任董事。从2003年1月至2003年11月，Homcy博士在Millennium Pharmaceuticals担任高级研发顾问，他于2002年加入了他们作为研发总裁。在此之前，从1995年到2002年，他担任COR Therapeutics, Inc.的研发执行副总裁，该公司是一家专注于心力衰竭治疗的生物制药公司；从1998年1月到2002年被Millennium Pharmaceuticals收购，他担任COR的董事。从1997年起，Homcy博士担任加州大学旧金山医学院（University of California at San Francisco Medical School）的临床医学教授和San Francisco VA Hospital的主治医生。从1994年到1995年，Homcy博士是American Cyanamid Company-Lederle Laboratories （ 现Wyeth-Ayerst Laboratories的分公司）医学研究部总裁。从1990年到1994年，Homcy博士是执行主任心血管和中枢神经系统研究部分Lederle实验室。从1991年到1995年Homcy博士还担任The Presbyterian Hospital, College of Physicians and Surgeons, at Columbia University in New York的主治医生。从1979年到1990年，他是 Massachusetts General Hospital的主治医生，以及哈佛医学院医学（Harvard Medical School）的副教授。Charles J. Homcy拥有约翰霍普金斯大学授予的医学学士学位和博士学位。
- Charles J. Homcy has served as a member of our Board since September 2003 as Co-Chairman of our Board from March 2010 to May 2013 and as Chairman of our Board from September 2003 to March 2010. Since May 2010 Dr. Homcy has served as a Venture Partner of Third Rock Ventures, a venture capital firm. Since 1997 Dr. Homcy has served as Clinical Professor of Medicine, University of California at San Francisco Medical School and as an attending physician at the San Francisco Veteran’s Administration Hospital. Dr. Homcy is a co-founder of Portola and served as President and Chief Executive Officer of Portola from September 2003 to April 2010 and was employed as an adviser to Portola from May 2010 to February 2012. He served as President, Research and Development at Millennium from February 2002 to January 2003 and senior adviser of Research and Development at Millennium from January 2003 to November 2003. From May 1995 to March 2002 he served as Executive Vice President of Research and Development of COR. Dr. Homcy is currently a director on the board of MyoKardia, Inc. and Global Blood Therapeutics, Inc. as well as a member of the Board of Trustees of Johns Hopkins University. Dr. Homcy also serves as a Scientific Advisor for Cytokinetics, Inc. Dr. Homcy holds an A.B. in Biology and an M.D. from Johns Hopkins University. Dr. Homcy is also a member of the Board of Trustees of John Hopkins University.
- H. Ward Wolff
-
H. Ward Wolff，2007年12月起担任公司执行副总裁和首席财务官。担任执行副总裁和首席财务官前，2006年6月至2007年12月，他担任公司董事会成员和审计委员会主席。加入公司前，2006年7月至2007年8月，他担任Nuvelo, Inc.（现ARCA biopharma, Inc.）的高级金融副总裁和首席财务官。2004年9月至2006年4月，担任Abgenix, Inc.的首席财务官和高级金融副总裁。2002年7月至2003年12月，他担任QuantumShift的首席财务官。1998至2002年1月，他担任DoubleTwist, Inc.的高级副总裁和首席财务官。1992至1998年，他担任Premenos Technology Corporation的金融和管理高级副总裁和首席财务官。1985至1992年，他担任Russell Reynolds Associates, Inc.执行董事。1974至1985年，他作为一名注册会计师，在Price Waterhouse & Co。担任包括高级审计经理在内的多个职位。他现任Portola Pharmaceuticals, Inc. 公司的董事会成员。他获有加利福利亚大学伯克利分校（University of California at Berkeley）的经济学学士学位，以及哈佛商学院（Harvard Business School）的工商管理硕士学位。
H. Ward Wolff has served as a member of our board of directors since December 2014. Mr. Wolff served as Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc. from 2007 until his retirement in March 2017. Prior to Sangamo, Mr. Wolff was with Nuvelo, Inc., where he served as Senior Vice President, Finance and Chief Financial Officer until its restructuring in August 2007. Prior to that, he was Chief Financial Officer and Senior Vice President, Finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist, Inc., a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including Senior Audit Manager. Mr. Wolff is a member of the board of directors of Portola Pharmaceuticals, Inc. From June 2006 until his appointment to Sangamo’s management team he was a member of Sangamo’s Board of Directors, serving as Chairman of the Audit Committee. Mr. Wolff received a B.A. degree in Economics from the University of California at Berkeley and an M.B.A. degree from Harvard Business School. - H. Ward Wolff，2007年12月起担任公司执行副总裁和首席财务官。担任执行副总裁和首席财务官前，2006年6月至2007年12月，他担任公司董事会成员和审计委员会主席。加入公司前，2006年7月至2007年8月，他担任Nuvelo, Inc.（现ARCA biopharma, Inc.）的高级金融副总裁和首席财务官。2004年9月至2006年4月，担任Abgenix, Inc.的首席财务官和高级金融副总裁。2002年7月至2003年12月，他担任QuantumShift的首席财务官。1998至2002年1月，他担任DoubleTwist, Inc.的高级副总裁和首席财务官。1992至1998年，他担任Premenos Technology Corporation的金融和管理高级副总裁和首席财务官。1985至1992年，他担任Russell Reynolds Associates, Inc.执行董事。1974至1985年，他作为一名注册会计师，在Price Waterhouse & Co。担任包括高级审计经理在内的多个职位。他现任Portola Pharmaceuticals, Inc. 公司的董事会成员。他获有加利福利亚大学伯克利分校（University of California at Berkeley）的经济学学士学位，以及哈佛商学院（Harvard Business School）的工商管理硕士学位。
- H. Ward Wolff has served as a member of our board of directors since December 2014. Mr. Wolff served as Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc. from 2007 until his retirement in March 2017. Prior to Sangamo, Mr. Wolff was with Nuvelo, Inc., where he served as Senior Vice President, Finance and Chief Financial Officer until its restructuring in August 2007. Prior to that, he was Chief Financial Officer and Senior Vice President, Finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist, Inc., a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including Senior Audit Manager. Mr. Wolff is a member of the board of directors of Portola Pharmaceuticals, Inc. From June 2006 until his appointment to Sangamo’s management team he was a member of Sangamo’s Board of Directors, serving as Chairman of the Audit Committee. Mr. Wolff received a B.A. degree in Economics from the University of California at Berkeley and an M.B.A. degree from Harvard Business School.
- Jeffrey W. Bird
-
Jeffrey W. Bird, M.D., Ph.D.，2008年11月以来，他担任Threshold Pharmaceuticals, Inc.的董事会成员。他是Sutter Hill Ventures（位于加州帕罗奥图的风险资本公司）的董事总经理。他曾担任Gilead Sciences的业务运营高级副总裁负责业务发展和商业活动。他还担任斯坦福大学（Stanford ）生物科学学位（1982年）和斯坦福大学（Stanford ）医学院的癌症生物学博士学位（1988年）和硕士学位（1992年）。他目前是Horizon Pharma, Inc.（上市公司）、Portola Pharmaceuticals, Inc.（上市公司）和一些私人生物技术公司的董事会成员。
Jeffrey W. Bird has served as a member of our board of directors since November 2008. Dr. Bird is a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982 a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of Portola Pharmaceuticals, Inc., a public company, and a number of private biotechnology companies. Dr. Bird was formerly a board member of Horizon Pharma, Inc., a public company. - Jeffrey W. Bird, M.D., Ph.D.，2008年11月以来，他担任Threshold Pharmaceuticals, Inc.的董事会成员。他是Sutter Hill Ventures（位于加州帕罗奥图的风险资本公司）的董事总经理。他曾担任Gilead Sciences的业务运营高级副总裁负责业务发展和商业活动。他还担任斯坦福大学（Stanford ）生物科学学位（1982年）和斯坦福大学（Stanford ）医学院的癌症生物学博士学位（1988年）和硕士学位（1992年）。他目前是Horizon Pharma, Inc.（上市公司）、Portola Pharmaceuticals, Inc.（上市公司）和一些私人生物技术公司的董事会成员。
- Jeffrey W. Bird has served as a member of our board of directors since November 2008. Dr. Bird is a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982 a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of Portola Pharmaceuticals, Inc., a public company, and a number of private biotechnology companies. Dr. Bird was formerly a board member of Horizon Pharma, Inc., a public company.
- John H. Johnson
-
John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. - John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
- John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization.
- Laura Brege
-
Laura Brege自2011年6月担任公司董事，自2012年9月，她曾担任Nodality公司的总裁兼首席执行官，这是一家生物技术公司，专注于治疗药物的开发。此前，Brege女士持有Onyx Pharmaceuticals公司的首席运营官兼执行副总裁兼首席商务官的职位。Onyx是一家生物制药公司，开发和销售用于癌症治疗的药物。在2006年加入Onyx之前，Brege女士曾是红岩资本管理（Red Rock Capital Management）的普通合伙人，这是一个风险投资公司，并担任COR Therapeutics公司的高级副总裁兼首席财务官，Brege女士目前担任阿卡迪亚制药公司（Acadia Pharmaceuticals Inc）（NASDAQ：ACAD），Delcath系统公司（NASDAQ：DCTH）和Aratana治疗公司（NASDAQ：PETX）的董事。从2007年至2011年她曾担任Angiotech制药公司的董事会成员。Brege女士获得了俄亥俄大学（Ohio University）学士学位，并拥有芝加哥大学（University of Chicago）的工商管理硕士学位。
Laura Brege,Ms. Brege has served as a director since June 2011. Since September 2015. Ms. Brege has been Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. From September 2012 to July 2015 Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a privately held biotechnology company focused in oncology and immunology. Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President, Chief Business Officer and Head of Corporate Affairs at Onyx Pharmaceuticals, Inc., a biopharmaceutical company that developed and marketed medicines for the treatment of cancer. Prior to joining Onyx in 2006 Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc. Ms. Brege currently serves as a director of Acadia Pharmaceuticals Inc. NASDAQ: ACAD, Aratana Therapeutics, Inc. (NASDAQ: PETX), Dynavax Technologies Corporation (NASDAQ: DVAX), and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). She previously served as a member of the board of directors of Angiotech Pharmaceuticals Inc. from 2007 to 2011 and Delcath Systems, Inc. from 2012 to 2014. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. - Laura Brege自2011年6月担任公司董事，自2012年9月，她曾担任Nodality公司的总裁兼首席执行官，这是一家生物技术公司，专注于治疗药物的开发。此前，Brege女士持有Onyx Pharmaceuticals公司的首席运营官兼执行副总裁兼首席商务官的职位。Onyx是一家生物制药公司，开发和销售用于癌症治疗的药物。在2006年加入Onyx之前，Brege女士曾是红岩资本管理（Red Rock Capital Management）的普通合伙人，这是一个风险投资公司，并担任COR Therapeutics公司的高级副总裁兼首席财务官，Brege女士目前担任阿卡迪亚制药公司（Acadia Pharmaceuticals Inc）（NASDAQ：ACAD），Delcath系统公司（NASDAQ：DCTH）和Aratana治疗公司（NASDAQ：PETX）的董事。从2007年至2011年她曾担任Angiotech制药公司的董事会成员。Brege女士获得了俄亥俄大学（Ohio University）学士学位，并拥有芝加哥大学（University of Chicago）的工商管理硕士学位。
- Laura Brege,Ms. Brege has served as a director since June 2011. Since September 2015. Ms. Brege has been Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. From September 2012 to July 2015 Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a privately held biotechnology company focused in oncology and immunology. Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President, Chief Business Officer and Head of Corporate Affairs at Onyx Pharmaceuticals, Inc., a biopharmaceutical company that developed and marketed medicines for the treatment of cancer. Prior to joining Onyx in 2006 Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc. Ms. Brege currently serves as a director of Acadia Pharmaceuticals Inc. NASDAQ: ACAD, Aratana Therapeutics, Inc. (NASDAQ: PETX), Dynavax Technologies Corporation (NASDAQ: DVAX), and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). She previously served as a member of the board of directors of Angiotech Pharmaceuticals Inc. from 2007 to 2011 and Delcath Systems, Inc. from 2012 to 2014. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
- William Lis
-
William Lis先生自2018年10月起一直担任再鼎医药有限公司独立董事。Lis先生拥有28年生物制药行业经验。Lis先生为Jasper Therapeutics,Inc的执行主席兼临时首席执行官，领导该公司进行2019年A系列融资。在此之前，Lis先生于2009年至2018年期间曾先后担任Portola Pharmaceuticals,Inc.的首席运营官及首席执行官兼董事，并于其后担任首席运营官。在Lis先生领导下，Portola成功由一间处于探索阶段的公司发展成为实现完全一体化的研发机构及商业组织，并且通过商业推广独立发现及开发Andexxa及Bevyxxa，以及将cerdulatinib推进至临床开发阶段。Lis先生领导公司合伙经营以及非公开及公开融资，包括于2013年进行首次公开招股。在Lis先生任职期间，该公司发展成为一间估值数十亿美元的公司，后于2020年更被Alexion Pharmaceuticals收购。Lis先生曾在Scios,Inc.（强生集团旗下公司）担任高管职务，离职前的最后职务为业务发展及新产品开发高级副总裁，努力领导Xarelto产品的引入授权、开发及上市前工作。Lis先生亦于Millennium Pharmaceuticals,Inc.（前称COR Therapeutics,Inc.）及Rhone Poulenc Rorer担任越来越重要的销售、营销、医疗事务及业务发展职务。Lis先生参与Integrilin、Lovenox及Rilutek等多种产品在美国上市。Lis先生担任新晋公司生物董事会成员，目前为Eidos Therapeutics,Inc.及Zai Laboratories,Inc.的独立董事。Lis先生拥有马里兰州大学（University of Maryland）理学士学位。
William Lis,Various board and executive positions at Jasper Therapeutics, Inc., including Chairperson of the Board of Directors (March 2022-Present) and Chief Executive Officer and Executive Chairman of the Board (November 2019-March 2022);Member of the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ) (December 2018-its acquisition by Bridge Bio Pharma, Inc. in January 2021);Various executive and board positions at Portola Pharmaceuticals, Inc. (later acquired by Alexion Pharmaceuticals, Inc. in 2020), including Chief Executive Officer and Member of the Board of Directors (December 2009-August 2018), Chief Operating Officer (2009), and Chief Business Officer (2008-2009);Various executive positions at Scios, Inc. (a Johnson & Johnson company) (2003-2008), including Senior Vice President of New Product Development and Business Development;Various roles of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) in sales, marketing, medical affairs, and business development (1998-2003);Member of the Biotechnology Innovation Organization ("BIO") Emerging Companies Section ("ECS") (2015-2016);B.S. from the University of Maryland. - William Lis先生自2018年10月起一直担任再鼎医药有限公司独立董事。Lis先生拥有28年生物制药行业经验。Lis先生为Jasper Therapeutics,Inc的执行主席兼临时首席执行官，领导该公司进行2019年A系列融资。在此之前，Lis先生于2009年至2018年期间曾先后担任Portola Pharmaceuticals,Inc.的首席运营官及首席执行官兼董事，并于其后担任首席运营官。在Lis先生领导下，Portola成功由一间处于探索阶段的公司发展成为实现完全一体化的研发机构及商业组织，并且通过商业推广独立发现及开发Andexxa及Bevyxxa，以及将cerdulatinib推进至临床开发阶段。Lis先生领导公司合伙经营以及非公开及公开融资，包括于2013年进行首次公开招股。在Lis先生任职期间，该公司发展成为一间估值数十亿美元的公司，后于2020年更被Alexion Pharmaceuticals收购。Lis先生曾在Scios,Inc.（强生集团旗下公司）担任高管职务，离职前的最后职务为业务发展及新产品开发高级副总裁，努力领导Xarelto产品的引入授权、开发及上市前工作。Lis先生亦于Millennium Pharmaceuticals,Inc.（前称COR Therapeutics,Inc.）及Rhone Poulenc Rorer担任越来越重要的销售、营销、医疗事务及业务发展职务。Lis先生参与Integrilin、Lovenox及Rilutek等多种产品在美国上市。Lis先生担任新晋公司生物董事会成员，目前为Eidos Therapeutics,Inc.及Zai Laboratories,Inc.的独立董事。Lis先生拥有马里兰州大学（University of Maryland）理学士学位。
- William Lis,Various board and executive positions at Jasper Therapeutics, Inc., including Chairperson of the Board of Directors (March 2022-Present) and Chief Executive Officer and Executive Chairman of the Board (November 2019-March 2022);Member of the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ) (December 2018-its acquisition by Bridge Bio Pharma, Inc. in January 2021);Various executive and board positions at Portola Pharmaceuticals, Inc. (later acquired by Alexion Pharmaceuticals, Inc. in 2020), including Chief Executive Officer and Member of the Board of Directors (December 2009-August 2018), Chief Operating Officer (2009), and Chief Business Officer (2008-2009);Various executive positions at Scios, Inc. (a Johnson & Johnson company) (2003-2008), including Senior Vice President of New Product Development and Business Development;Various roles of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) in sales, marketing, medical affairs, and business development (1998-2003);Member of the Biotechnology Innovation Organization ("BIO") Emerging Companies Section ("ECS") (2015-2016);B.S. from the University of Maryland.
- Laura Brege
-
Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., HLS Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc. and T-knife Therapeutics, Inc. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. - Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大学工商管理硕士学位。
- Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., HLS Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc. and T-knife Therapeutics, Inc. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
- David Stump
-
2013年9月以来，David Stump M.D。担任董事。从1999年11月，他担任执行副总裁，负责人类基因组科学研究和开发，直到2012年12月退休。他担任Sunesis Pharmaceuticals的董事，一家上市控股公司。他担任Dendreon公司的董事，一家上市控股公司。
David Stump has served as a member of our Board since September 2015. Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. Prior to joining Human Genome Sciences, Dr. Stump held various roles at Genentech, Inc., from 1989 to 1999 most recently as Vice President, Clinical Research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump is a member of the Board of Directors of Regenxbio, Inc., Sunesis Pharmaceuticals, Inc. and MacroGenics, Inc. Dr. Stump is also a member of the Board of Trustees of Earlham College. Dr. Stump is board certified in Internal Medicine, Hematology and Medical Oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He holds an A.B. from Earlham College and an M.D. from Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. - 2013年9月以来，David Stump M.D。担任董事。从1999年11月，他担任执行副总裁，负责人类基因组科学研究和开发，直到2012年12月退休。他担任Sunesis Pharmaceuticals的董事，一家上市控股公司。他担任Dendreon公司的董事，一家上市控股公司。
- David Stump has served as a member of our Board since September 2015. Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. Prior to joining Human Genome Sciences, Dr. Stump held various roles at Genentech, Inc., from 1989 to 1999 most recently as Vice President, Clinical Research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump is a member of the Board of Directors of Regenxbio, Inc., Sunesis Pharmaceuticals, Inc. and MacroGenics, Inc. Dr. Stump is also a member of the Board of Trustees of Earlham College. Dr. Stump is board certified in Internal Medicine, Hematology and Medical Oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He holds an A.B. from Earlham College and an M.D. from Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology, and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium.
高管简历
中英对照 | 中文 | 英文- Tao Fu
Tao Fu，2015年6月以来，他一直担任Portola Pharmaceuticals, Inc.的执行副总裁、首席商务官。2014年1月至2015年6月，他曾担任Bristol-Myers Squibb（生物制药公司）的副总裁兼并购和联盟管理主管。2010年3月至2014年1月，他曾担任Janssen Pharmaceuticals, Inc.（Johnson & Johnson的制药集团）的商业开发副总裁、并购主管。从2006年9月到2010年3月，他担任Janssen公司的副总裁，负责商务开发。从2002年到2006年，他担任Scios Inc（生物制药公司，被Johnson & Johnson收购）的副总裁，负责公司业务发展。从2001年到2002年，他担任麦肯锡咨询公司（McKinsey & Company）（管理咨询公司）的顾问。他此前曾担任Becton, Dickinson and Company（医疗技术公司）的业务开发经理（1997年至2000年）。他是特许金融分析师。他完成了Tsinghua University的本科学习，持有the University of Rochester的生物学硕士学位，以及范德堡大学欧文管理学院（the Owen Graduate School of Management at Vanderbilt University）的工商管理硕士学位。
Tao Fu has been Zai Lab Director since 2017 and has served as Zai Lab's President and Chief Operating Officer since September 2018. Prior to joining Zai Lab, he was Executive Vice President, Chief Commercial and Business Officer of Portola Pharmaceuticals, Inc. from June 2015 to September 2018. Prior to joining Portola in June 2015 Mr. Fu was Vice President, business development, head of M&A and alliance management at BMS. Between 2003 and 2014 Mr. Fu worked at Johnson & Johnson in a number of roles, most recently as Vice President, business development. Prior to joining Johnson & Johnson, Mr. Fu held managerial positions with Scios Inc., a biotechnology company in California; McKinsey & Company, a global management consulting firm; and Becton Dickinson, a leading medical device company. Mr. Fu received a master of science in cell biology from the University of Rochester, and a master of business administration in finance and marketing from Vanderbilt University. Mr. Fu did his undergraduate studies in biology at Tsinghua University from 1989 to 1992 and earned a Chartered Financial Analyst CFA designation.- Tao Fu，2015年6月以来，他一直担任Portola Pharmaceuticals, Inc.的执行副总裁、首席商务官。2014年1月至2015年6月，他曾担任Bristol-Myers Squibb（生物制药公司）的副总裁兼并购和联盟管理主管。2010年3月至2014年1月，他曾担任Janssen Pharmaceuticals, Inc.（Johnson & Johnson的制药集团）的商业开发副总裁、并购主管。从2006年9月到2010年3月，他担任Janssen公司的副总裁，负责商务开发。从2002年到2006年，他担任Scios Inc（生物制药公司，被Johnson & Johnson收购）的副总裁，负责公司业务发展。从2001年到2002年，他担任麦肯锡咨询公司（McKinsey & Company）（管理咨询公司）的顾问。他此前曾担任Becton, Dickinson and Company（医疗技术公司）的业务开发经理（1997年至2000年）。他是特许金融分析师。他完成了Tsinghua University的本科学习，持有the University of Rochester的生物学硕士学位，以及范德堡大学欧文管理学院（the Owen Graduate School of Management at Vanderbilt University）的工商管理硕士学位。
- Tao Fu has been Zai Lab Director since 2017 and has served as Zai Lab's President and Chief Operating Officer since September 2018. Prior to joining Zai Lab, he was Executive Vice President, Chief Commercial and Business Officer of Portola Pharmaceuticals, Inc. from June 2015 to September 2018. Prior to joining Portola in June 2015 Mr. Fu was Vice President, business development, head of M&A and alliance management at BMS. Between 2003 and 2014 Mr. Fu worked at Johnson & Johnson in a number of roles, most recently as Vice President, business development. Prior to joining Johnson & Johnson, Mr. Fu held managerial positions with Scios Inc., a biotechnology company in California; McKinsey & Company, a global management consulting firm; and Becton Dickinson, a leading medical device company. Mr. Fu received a master of science in cell biology from the University of Rochester, and a master of business administration in finance and marketing from Vanderbilt University. Mr. Fu did his undergraduate studies in biology at Tsinghua University from 1989 to 1992 and earned a Chartered Financial Analyst CFA designation.
- William Lis
William Lis先生自2018年10月起一直担任再鼎医药有限公司独立董事。Lis先生拥有28年生物制药行业经验。Lis先生为Jasper Therapeutics,Inc的执行主席兼临时首席执行官，领导该公司进行2019年A系列融资。在此之前，Lis先生于2009年至2018年期间曾先后担任Portola Pharmaceuticals,Inc.的首席运营官及首席执行官兼董事，并于其后担任首席运营官。在Lis先生领导下，Portola成功由一间处于探索阶段的公司发展成为实现完全一体化的研发机构及商业组织，并且通过商业推广独立发现及开发Andexxa及Bevyxxa，以及将cerdulatinib推进至临床开发阶段。Lis先生领导公司合伙经营以及非公开及公开融资，包括于2013年进行首次公开招股。在Lis先生任职期间，该公司发展成为一间估值数十亿美元的公司，后于2020年更被Alexion Pharmaceuticals收购。Lis先生曾在Scios,Inc.（强生集团旗下公司）担任高管职务，离职前的最后职务为业务发展及新产品开发高级副总裁，努力领导Xarelto产品的引入授权、开发及上市前工作。Lis先生亦于Millennium Pharmaceuticals,Inc.（前称COR Therapeutics,Inc.）及Rhone Poulenc Rorer担任越来越重要的销售、营销、医疗事务及业务发展职务。Lis先生参与Integrilin、Lovenox及Rilutek等多种产品在美国上市。Lis先生担任新晋公司生物董事会成员，目前为Eidos Therapeutics,Inc.及Zai Laboratories,Inc.的独立董事。Lis先生拥有马里兰州大学（University of Maryland）理学士学位。
William Lis,Various board and executive positions at Jasper Therapeutics, Inc., including Chairperson of the Board of Directors (March 2022-Present) and Chief Executive Officer and Executive Chairman of the Board (November 2019-March 2022);Member of the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ) (December 2018-its acquisition by Bridge Bio Pharma, Inc. in January 2021);Various executive and board positions at Portola Pharmaceuticals, Inc. (later acquired by Alexion Pharmaceuticals, Inc. in 2020), including Chief Executive Officer and Member of the Board of Directors (December 2009-August 2018), Chief Operating Officer (2009), and Chief Business Officer (2008-2009);Various executive positions at Scios, Inc. (a Johnson & Johnson company) (2003-2008), including Senior Vice President of New Product Development and Business Development;Various roles of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) in sales, marketing, medical affairs, and business development (1998-2003);Member of the Biotechnology Innovation Organization ("BIO") Emerging Companies Section ("ECS") (2015-2016);B.S. from the University of Maryland.- William Lis先生自2018年10月起一直担任再鼎医药有限公司独立董事。Lis先生拥有28年生物制药行业经验。Lis先生为Jasper Therapeutics,Inc的执行主席兼临时首席执行官，领导该公司进行2019年A系列融资。在此之前，Lis先生于2009年至2018年期间曾先后担任Portola Pharmaceuticals,Inc.的首席运营官及首席执行官兼董事，并于其后担任首席运营官。在Lis先生领导下，Portola成功由一间处于探索阶段的公司发展成为实现完全一体化的研发机构及商业组织，并且通过商业推广独立发现及开发Andexxa及Bevyxxa，以及将cerdulatinib推进至临床开发阶段。Lis先生领导公司合伙经营以及非公开及公开融资，包括于2013年进行首次公开招股。在Lis先生任职期间，该公司发展成为一间估值数十亿美元的公司，后于2020年更被Alexion Pharmaceuticals收购。Lis先生曾在Scios,Inc.（强生集团旗下公司）担任高管职务，离职前的最后职务为业务发展及新产品开发高级副总裁，努力领导Xarelto产品的引入授权、开发及上市前工作。Lis先生亦于Millennium Pharmaceuticals,Inc.（前称COR Therapeutics,Inc.）及Rhone Poulenc Rorer担任越来越重要的销售、营销、医疗事务及业务发展职务。Lis先生参与Integrilin、Lovenox及Rilutek等多种产品在美国上市。Lis先生担任新晋公司生物董事会成员，目前为Eidos Therapeutics,Inc.及Zai Laboratories,Inc.的独立董事。Lis先生拥有马里兰州大学（University of Maryland）理学士学位。
- William Lis,Various board and executive positions at Jasper Therapeutics, Inc., including Chairperson of the Board of Directors (March 2022-Present) and Chief Executive Officer and Executive Chairman of the Board (November 2019-March 2022);Member of the Board of Directors of Eidos Therapeutics, Inc. (NASDAQ) (December 2018-its acquisition by Bridge Bio Pharma, Inc. in January 2021);Various executive and board positions at Portola Pharmaceuticals, Inc. (later acquired by Alexion Pharmaceuticals, Inc. in 2020), including Chief Executive Officer and Member of the Board of Directors (December 2009-August 2018), Chief Operating Officer (2009), and Chief Business Officer (2008-2009);Various executive positions at Scios, Inc. (a Johnson & Johnson company) (2003-2008), including Senior Vice President of New Product Development and Business Development;Various roles of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) in sales, marketing, medical affairs, and business development (1998-2003);Member of the Biotechnology Innovation Organization ("BIO") Emerging Companies Section ("ECS") (2015-2016);B.S. from the University of Maryland.
- John T. Curnutte
John T. Curnutte，2011年2月起，担任本公司的高级研发执行副总裁。2010年4月至2011年1月，他是一名独立顾问。2008年5月至2010年3月，他担任生物技术公司3-V Biosciences的首席执行官。2000年9月至2008年5月，他担任Schering-Plough Biopharma的总裁，这是Schering-Plough Corporation的子公司；以及Schering Plough Research Institute的研发副总裁，这是一个制药保健公司。1993年8月至2000年9月，他在生物技术公司Genentech担任过多个管理职务。他目前是Stanford University School of Medicine的儿科临床兼职教授，也是一名医疗员工。他获得了Harvard University的生物化学与分子生物学士学位，在Harvard Medical School获得生物化学硕士、博士学位。
John T. Curnutte has served as our Executive Vice President of Research and Development since February 2011. From May 2015 to June 2016 Dr. Curnutte served as a member of the Board of Directors of Diadexus, Inc., a medical diagnostics company. From April 2010 to January 2011 Dr. Curnutte served as an independent consultant. From May 2008 to March 2010 Dr. Curnutte served as the Chief Executive Officer of 3-V Biosciences, Inc., a biotechnology company. From September 2000 to May 2008 he served as President of Schering-Plough Biopharma, a biopharmaceutical subsidiary of Schering-Plough Corporation, and Senior Vice President of Discovery Research at Schering Plough Research Institute, a pharmaceutical and healthcare company. From August 1993 to September 2000 Dr. Curnutte held various senior management positions at Genentech, Inc., a biotechnology company. Dr. Curnutte was an adjunct clinical professor of pediatrics at the Stanford University School of Medicine and a member of the medical staff from 1993 to 2013. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from Harvard University and an M.D. and a Ph.D. in Biological Chemistry from Harvard Medical School.- John T. Curnutte，2011年2月起，担任本公司的高级研发执行副总裁。2010年4月至2011年1月，他是一名独立顾问。2008年5月至2010年3月，他担任生物技术公司3-V Biosciences的首席执行官。2000年9月至2008年5月，他担任Schering-Plough Biopharma的总裁，这是Schering-Plough Corporation的子公司；以及Schering Plough Research Institute的研发副总裁，这是一个制药保健公司。1993年8月至2000年9月，他在生物技术公司Genentech担任过多个管理职务。他目前是Stanford University School of Medicine的儿科临床兼职教授，也是一名医疗员工。他获得了Harvard University的生物化学与分子生物学士学位，在Harvard Medical School获得生物化学硕士、博士学位。
- John T. Curnutte has served as our Executive Vice President of Research and Development since February 2011. From May 2015 to June 2016 Dr. Curnutte served as a member of the Board of Directors of Diadexus, Inc., a medical diagnostics company. From April 2010 to January 2011 Dr. Curnutte served as an independent consultant. From May 2008 to March 2010 Dr. Curnutte served as the Chief Executive Officer of 3-V Biosciences, Inc., a biotechnology company. From September 2000 to May 2008 he served as President of Schering-Plough Biopharma, a biopharmaceutical subsidiary of Schering-Plough Corporation, and Senior Vice President of Discovery Research at Schering Plough Research Institute, a pharmaceutical and healthcare company. From August 1993 to September 2000 Dr. Curnutte held various senior management positions at Genentech, Inc., a biotechnology company. Dr. Curnutte was an adjunct clinical professor of pediatrics at the Stanford University School of Medicine and a member of the medical staff from 1993 to 2013. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from Harvard University and an M.D. and a Ph.D. in Biological Chemistry from Harvard Medical School.
- Mardi C. Dier
Mardi C. Dier，2006年8月起，担任本公司的执行副总裁、首席财务官。2003年6月至2006年7月，她在生物制药公司Chiron Corporation担任投资者关系副总裁。1994-2001，她担任证券公司Prudential Securities的投资银行部总监。之前，1986-1990，她是会计师事务所KPMG LLP审计部门的监管高级会计师。她获得了Stanford University的生物学士学位、Anderson Graduate School of Management at the University of California, Los Angeles。的工商管理硕士学位。
Mardi C. Dier has served as a member of Prelude Therapeutics Inc board of directors since August 2020. Ms. Dier most recently served as Executive Vice President and Chief Financial Officer, and also as Chief Business Officer, of Portola Pharmaceuticals, Inc., a biopharmaceutical company, from November 2013 and October 2018 respectively, until its acquisition by Alexion Pharmaceuticals in July 2020 and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006 Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001 Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Ms. Dier currently serves as a director, and member of the audit committee, of Adamas Pharmaceuticals, Inc., a biopharmaceutical company, and as a director of ORIC Pharmaceuticals, Inc. Ms. Dier received a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.- Mardi C. Dier，2006年8月起，担任本公司的执行副总裁、首席财务官。2003年6月至2006年7月，她在生物制药公司Chiron Corporation担任投资者关系副总裁。1994-2001，她担任证券公司Prudential Securities的投资银行部总监。之前，1986-1990，她是会计师事务所KPMG LLP审计部门的监管高级会计师。她获得了Stanford University的生物学士学位、Anderson Graduate School of Management at the University of California, Los Angeles。的工商管理硕士学位。
- Mardi C. Dier has served as a member of Prelude Therapeutics Inc board of directors since August 2020. Ms. Dier most recently served as Executive Vice President and Chief Financial Officer, and also as Chief Business Officer, of Portola Pharmaceuticals, Inc., a biopharmaceutical company, from November 2013 and October 2018 respectively, until its acquisition by Alexion Pharmaceuticals in July 2020 and as a Senior Vice President and Chief Financial Officer from August 2006 to November 2013. From 2003 to 2006 Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001 Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, an accounting firm, from 1986 to 1990. Ms. Dier currently serves as a director, and member of the audit committee, of Adamas Pharmaceuticals, Inc., a biopharmaceutical company, and as a director of ORIC Pharmaceuticals, Inc. Ms. Dier received a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.